BioAdaptives, Inc.

Overview

BioAdaptives is a Delaware research and development nutraceutical company that markets natural plant, algal, and cyanobacteria-based products and related medical devices to support human and animal health and wellness. Its strategy includes reformulating and expanding product lines, pursuing partnerships in telehealth and medical devices, and using direct-to-consumer marketing and affiliate programs. The company outsources nutraceutical manufacturing and does not plan in-house device manufacturing due to capital considerations. Since 2024 it has relied on external financing, including convertible debt and new investment partners.

Product and market focus

Core focus areas:

• Nootropic/cognitive health
• Anti-aging and regenerative wellness
• Weight control and metabolic health
• Relaxation and pain relief
• Broad antiviral benefits

Key products and development status:

• MyndMed: Targets immediate cognitive enhancement (focus, clarity, motivation), medium-term resilience and memory gains, and long-term neuroprotection and brain health.
• Xcellara: Regenerative wellness formula intended to activate stem cells for cellular regeneration; reported positive effects in market testing for individuals with chronic fatigue.
• Zeranovia: Natural weight loss supplement designed to complement GLP-1/GIP therapies; promoted for appetite suppression, improved insulin sensitivity, muscle mass preservation, and nutritional support. Trial participants reportedly lost 5–11 pounds in 7–10 days.
• Wynovia: Formulated to reduce lean muscle loss during dieting.
• PawPa Regen: Canine product line of regenerative dog chews aimed at enhancing quality of life for senior dogs, supporting energy and anti-aging benefits.
• LungFlute™: FDA-cleared Class II medical device acquired in April 2024. Initially marketed via an FDA-cleared Lung Flute program, the company plans to expand its use into medical communities, pharmacies, gyms, athletic clubs, and senior communities domestically and internationally.

Product timing:

• Preparations for PawPa Regen and MyndMed reformulation began in 2024. The company aimed to introduce new products beginning in Q2 2025 and has started rollouts in 2025.
• The company is pursuing additional agreements with medical device manufacturers, IP owners, and marketing partners.

Marketing, sales, and distribution

• Direct-to-consumer digital marketing through social media, email campaigns, and a consumer website with health-focused content.
• Telehealth partnerships to position supplements as companion and standalone solutions within virtual healthcare services.
• An affiliate program that engages influencers and marketing partners using endorsements, affiliate links, and promo codes.
• Plans for international expansion into markets and medical communities outside the U.S.

Manufacturing and operations

• Nutraceuticals are marketed as dietary supplements or natural foods and avoid health/disease cure claims to comply with regulations.
• Active ingredients are plant-, fungi-, algae-, or cyanobacteria-based and sourced from global suppliers that follow compliance and sustainable practices.
• Nutraceutical manufacturing is outsourced; the company does not plan to build or acquire in-house device manufacturing facilities because of higher capital and amortization costs.
• Following the 2024 LungFlute acquisition, the company plans to expand adoption through telehealth and physician networks.

Employees and resources

• One full-time executive employee.
• Uses hourly labor, outside consultants, and professional service providers (legal, accounting, etc.) as needed to manage operations and growth.

Financial snapshot

• The company has relied on investment funding to support operations and has sought new investment partners since May 2024, including offerings for preferred D shares and use of convertible debt historically.
• Publicly reported share structure (as of March 24, 2026): 12,008,659 outstanding common shares; 7,006,478 common shares on deposit with CEDE & Co. and publicly tradable; the remainder held by early purchasers/service providers and eligible for sale under Rule 144. Outstanding preferred stock: 1,219,049 shares across Series A, B, C, and D.
• Corporate actions: 1-for-300 reverse stock split (resolved October 28, 2024) and a 1-for-1 stock dividend (approved December 3, 2024).

Governance and public market status

• Quoted on OTC Pink Sheets and classified as a penny stock, with risks typical of thinly traded, volatile securities.
• Governance functions are currently self-determined; the company has not implemented independent audit or compensation committees and anticipates conforming to governance requirements as needed while managing associated costs.

Risks and operating context

• The company has acknowledged substantial doubt about continuing as a going concern due to limited revenues and dependence on external financing.
• Regulatory exposure exists around nutraceutical and medical device rules and product claims.
• Operational risks include reliance on key personnel, outsourced manufacturing, supply chain vulnerabilities, and the need to scale marketing and operations amid funding constraints.
• Market risks include limited trading volume, potential dilution from future equity offerings, and conversion of preferred securities.

Concise takeaway

BioAdaptives develops and markets plant- and microbiology-based nutraceuticals and wellness products focused on cognitive health, weight management, aging, and general wellness, and owns an FDA-cleared medical device (LungFlute). The company outsources manufacturing, pursues licensing and partnership opportunities, and sells primarily through DTC and telehealth-enabled channels with an affiliate network. It operates with a very small full-time staff, relies on contractors and consultants, and depends on external financing to fund operations.